Roche introduces Sulli the Diabetes Guru, a voice-activated resource for people with diabetes
- On-demand, voice-activated support for people with diabetes
- Answers questions and provides tips on diet, exercise, motivation and more
- Available now at no cost on Amazon Alexa, coming soon on Google Assistant
INDIANAPOLIS, August 4, 2020- Managing insulin-dependent diabetes is no easy task and people living with the condition often have questions. Now, thanks to Sulli the Diabetes Guru, all they need to do is ask.
Sulli the Diabetes Guru, a voice-activated assistant brings 40 years of experience and understanding from Roche Diabetes Care directly into the homes of people with diabetes. Available 24/7, Sulli the Diabetes Guru is a knowledgeable and supportive virtual source of diabetes information, lifestyle tips and advice on diet, exercise, medication, blood glucose monitoring and more. This new diabetes support service is available free of charge on Amazon Alexa and Google Assistant. To ask a question, users just need to say: 'Talk to Sulli the Diabetes Guru’.
"Diabetes is a full-time job and can be overwhelming, especially during these uncertain times,” said Matt Logan, Vice President of Marketing, Roche Diabetes Care. “With Sulli the Diabetes Guru just a voice-command away, getting expert answers and diabetes management support as easy as picking up the phone or messaging a friend."
Sulli the Diabetes Guru can respond to important questions like, What is high blood sugar? or What should I be eating? or Is it okay to exercise before taking a blood sugar test? as well as set reminders to take medication, give lifestyle tips, and help find the nearest blood glucose monitor retailer.
Sulli the Diabetes Guru and Roche Diabetes Care do not provide medical advice. All content is approved by Roche Diabetes Care, and is consistent with the company’s mission to help people with diabetes think less about their daily diabetes routine and experience true relief day and night.
“Creating a voice experience to assist people with diabetes is another step in our active preparation for a future in which integration of digital technologies will improve self-care and consolidate relevant data for personalized dialogue with healthcare providers,” added Logan. “We will continue to develop content and features for Sulli the Diabetes Guru that can be expanded across platforms and help empower people with diabetes to live their best life.”
For additional information, visit www.accu-chek.com/Sulli.
About Roche Diabetes Care
Roche Diabetes Care has been pioneering innovative diabetes technologies and services for more than 40 years. More than 5,500 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target ranges and experience true relief from the daily therapy routines.
Being a global leader in integrated Personalized Diabetes Management (iPDM), Roche Diabetes Care collaborates with thought leaders around the globe, including people with diabetes, caregivers, healthcare providers and payers. Roche Diabetes Care aims to transform and advance care provision and foster sustainable care structures. Under the brands RocheDiabetes, Accu-Chek and mySugr, comprising glucose monitoring, insulin delivery systems and digital solutions, Roche Diabetes Care unites with its partners to create patient-centred value. By building and collaborating in an open ecosystem, connecting devices and digital solutions as well as contextualise relevant data points, Roche Diabetes Care enables deeper insights and a better understanding of the disease, leading to personalised and effective therapy adjustments. For better outcomes and true relief.
Since 2017, mySugr one of the most popular diabetes management apps is part of Roche Diabetes Care.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
For more information please contact:
- Amy Lynn (firstname.lastname@example.org)